Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Botanical research centers

This article was originally published in The Tan Sheet

Executive Summary

NCCAM and NIH's Office of Dietary Supplements are co-funding five-year grants for five research centers investigating "a variety of widely consumed botanicals from flaxseed to tarragon," NCCAM Director Stephen Straus, MD, announces April 7. The Memorial Sloan-Kettering Cancer Center in New York will research botanicals that may modulate immune function, including echinacea and Chinese herbal formulations. Metabolic syndrome, obesity and diabetes are the focus of a partnership between Rutgers and Louisiana State University. Other study areas include anti-inflammatory actions of botanical lipids at Wake Forest and Harvard; women's health at the University of Illinois-Chicago; and age-related diseases at Purdue, Rutgers and the University of Alabama. First-year funding for all five combined totals about $6.75 mil...

You may also be interested in...



Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty

The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.

Topics

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel